You are browsing in:
Tag: frunevetmab
vet examine dog in clinic with client

Anti-nerve growth factor monoclonal antibodies – What is the evidence?

/0 Comments/in /by

Published 29 May 2025 | Updated 29 July 2025 |
This feature brings together published evidence about the potential use of biomarkers in the diagnosis and management of cancer in veterinary patients and provides an overview of the types of tests currently available.

Read more →
Veterinarian doctor examining the leg of a cat

Frunevetmab, a felinized anti-nerve growth factor monoclonal antibody, for the treatment of pain from osteoarthritis in cats

/0 Comments/in , , /by

M.E. Gruen, J.A.E. Myers, J-K.S. Tena, C. Becskei, D.M. Cleaver and B.D.X. Lascelles | Journal of Veterinary Internal Medicine | November/December 2021
The aim of this randomised, placebo-controlled, double-blind study was to evaluate the efficacy of frunevetmab, a felinized anti-nerve growth factor monoclonal antibody in cats with naturally occurring osteoarthritic (OA) pain…

Read more →
cat on the stairs

Efficacy and safety of an anti-nerve growth factor antibody (Frunevetmab) for the treatment of degenerative joint disease-associated chronic pain in cats: A multisite pilot field study

/0 Comments/in , , /by

M.E. Gruen, J.A.E. Myers and B. D. X. Lascelles | Frontiers in Veterinary Science | May 2021
The aim of this randomised placebo-controlled, double-blinded trial was to evaluate the safety and efficacy of two administration routes of frunevetmab compared to placebo in the treatment of degenerative joint disease (DJD)-associated pain in client-owned cats…

Read more →